DK3360538T3 - Injicerbar, flydende sammensætning omfattende buprenorphin - Google Patents

Injicerbar, flydende sammensætning omfattende buprenorphin Download PDF

Info

Publication number
DK3360538T3
DK3360538T3 DK17205986.7T DK17205986T DK3360538T3 DK 3360538 T3 DK3360538 T3 DK 3360538T3 DK 17205986 T DK17205986 T DK 17205986T DK 3360538 T3 DK3360538 T3 DK 3360538T3
Authority
DK
Denmark
Prior art keywords
buprenorphine
liquid composition
injectable liquid
injectable
composition
Prior art date
Application number
DK17205986.7T
Other languages
English (en)
Inventor
Richard L Norton
Andrew Watkins
Mingxing Zhou
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3360538(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Application granted granted Critical
Publication of DK3360538T3 publication Critical patent/DK3360538T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
DK17205986.7T 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin DK3360538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
EP11728037.0A EP2579874B1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
DK3360538T3 true DK3360538T3 (da) 2023-03-06

Family

ID=42471306

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11728037.0T DK2579874T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin
DK17205986.7T DK3360538T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11728037.0T DK2579874T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin

Country Status (31)

Country Link
US (1) US8921387B2 (da)
EP (3) EP3360538B1 (da)
JP (2) JP5986072B2 (da)
KR (1) KR101865689B1 (da)
CN (1) CN103079544B (da)
AU (1) AU2011263478B2 (da)
BR (1) BR112012031290A2 (da)
CA (1) CA2801676C (da)
CL (1) CL2012003462A1 (da)
CO (1) CO6670529A2 (da)
CY (1) CY1120761T1 (da)
DK (2) DK2579874T3 (da)
ES (2) ES2939612T3 (da)
FI (1) FI3360538T3 (da)
GB (2) GB2513267B (da)
HR (1) HRP20180118T1 (da)
HU (1) HUE038275T2 (da)
IL (2) IL223488A (da)
LT (1) LT2579874T (da)
MX (1) MX339209B (da)
MY (1) MY171625A (da)
NO (1) NO2579874T3 (da)
NZ (1) NZ604026A (da)
PL (1) PL2579874T3 (da)
PT (1) PT2579874T (da)
RS (1) RS56820B1 (da)
RU (1) RU2607498C2 (da)
SG (1) SG186200A1 (da)
SI (1) SI2579874T1 (da)
WO (1) WO2011154724A2 (da)
ZA (1) ZA201209233B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
EA201491875A1 (ru) 2012-04-17 2015-04-30 Пурдью Фарма Л.П. Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
DK2877155T3 (da) * 2012-07-26 2021-01-18 Camurus Ab Opioidformuleringer
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9592227B2 (en) * 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3134070B1 (en) * 2014-04-21 2020-09-23 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
DK3134068T3 (da) 2014-04-21 2021-10-04 Heron Therapeutics Inc Langtidsvirkende polymerafgivelsessystemer
MX2016013829A (es) 2014-04-28 2017-05-12 Orphomed Inc Dimeros activos farmaceuticamente ligados a traves de grupos hidroxilo fenolicos.
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
NZ731309A (en) * 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
WO2017024027A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
LT3377041T (lt) 2015-11-16 2023-12-27 Medincell S.A. Farmaciškai aktyvių komponentų suskaidymo ir (arba) nukreipimo į sinovinį audinį būdas
HUE060906T2 (hu) * 2016-09-13 2023-04-28 Alar Pharmaceuticals Inc Nyújtott felszabadulású buprenorfin-készítmények
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
ES2965836T3 (es) 2018-01-22 2024-04-17 Foresee Pharmaceuticals Co Ltd Composición farmacéutica para administración de liberación mantenida de buprenorfina
TWI838372B (zh) * 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DK0754032T3 (da) 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
DE60325511D1 (de) * 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc FORMULATIONS FOR CELL-PLAN-DEPENDENT CANCER
KR20070083941A (ko) * 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
AU2005304435B8 (en) * 2004-11-10 2011-06-23 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
PT2115029E (pt) 2007-02-15 2015-10-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
PT2579874T (pt) 2018-01-29
EP4218720A1 (en) 2023-08-02
EP2579874B1 (en) 2018-01-10
EP2579874A2 (en) 2013-04-17
LT2579874T (lt) 2018-02-12
CA2801676A1 (en) 2011-12-15
GB2513267A (en) 2014-10-22
WO2011154724A2 (en) 2011-12-15
SG186200A1 (en) 2013-01-30
GB201413064D0 (en) 2014-09-03
HRP20180118T1 (hr) 2018-03-09
IL223488A (en) 2017-10-31
JP5986072B2 (ja) 2016-09-06
RU2012157244A (ru) 2014-07-20
DK2579874T3 (da) 2018-01-29
MX2012014335A (es) 2013-03-05
MY171625A (en) 2019-10-21
CL2012003462A1 (es) 2013-04-01
US8921387B2 (en) 2014-12-30
SI2579874T1 (en) 2018-03-30
BR112012031290A2 (pt) 2016-11-01
ZA201209233B (en) 2014-04-30
HUE038275T2 (hu) 2018-10-29
FI3360538T3 (fi) 2023-03-22
KR20130135026A (ko) 2013-12-10
CO6670529A2 (es) 2013-05-15
CA2801676C (en) 2018-08-07
NO2579874T3 (da) 2018-06-09
RS56820B1 (sr) 2018-04-30
AU2011263478A1 (en) 2013-01-10
PL2579874T3 (pl) 2018-05-30
GB2513267B (en) 2015-03-18
GB201009549D0 (en) 2010-07-21
WO2011154724A9 (en) 2012-08-16
JP2013533230A (ja) 2013-08-22
CY1120761T1 (el) 2019-12-11
WO2011154724A3 (en) 2012-07-12
US20130210853A1 (en) 2013-08-15
NZ604026A (en) 2015-01-30
ES2656938T3 (es) 2018-03-01
AU2011263478B2 (en) 2015-01-22
ES2939612T3 (es) 2023-04-25
EP3360538B1 (en) 2023-02-15
MX339209B (es) 2016-04-15
CN103079544A (zh) 2013-05-01
GB2481018B (en) 2015-03-18
IL254417A0 (en) 2017-11-30
KR101865689B1 (ko) 2018-06-08
JP6251774B2 (ja) 2017-12-20
JP2016155865A (ja) 2016-09-01
RU2607498C2 (ru) 2017-01-10
GB2481018A (en) 2011-12-14
EP3360538A1 (en) 2018-08-15
CN103079544B (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
DK3360538T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
SMT201700008B (it) Composizione farmaceutica
DK3257890T3 (da) Tværbindelig sammensætning
BR112012031667A2 (pt) composição
SMT201600458B (it) Composizioni comprendenti buprenorfina
BR112013022112A2 (pt) composição
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112013022102A2 (pt) composição
DK3246018T3 (da) Farmaceutisk sammensætning
DK2686017T3 (da) Oftalmisk sammensætning
BR112013016037A2 (pt) composição em gel.
BR112012032683A2 (pt) composição
BR112014004395A2 (pt) composição
SMT201700110B (it) Composizione immunogena
BR112014032798A2 (pt) composição
EP2522643A4 (en) CONCRETE COMPOSITION
EE201300005A (et) Ravimkoostis
BR112013014204A2 (pt) composições de sucops espumantes
BR112013015602A2 (pt) nova composição farmacèutica
EA201201176A1 (ru) Битумная композиция
BR112013033808A2 (pt) composição
BR112012032980A2 (pt) composição
ZA201308514B (en) Asphalt composition
BR112013000356A2 (pt) formulação farmacêutica injetável de malfalano
EP2878633A4 (en) curing composition